afamelanotide (Scenesse) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Afamelanotide (SCENESSE) is a synthetic α-melanocyte stimulating hormone analog and first-in-class melanocortin-1 receptor agonist that is approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria. Afamelanotide differs from endogenous α-melanocyte stimulating hormone at the fourth and seventh amino acid residues, increasing its resistance to immediate degradation and increasing its binding time to melanocortin-1 receptor. Afamelanotide is mimic the pharmacological activity of α-melanocyte stimulating hormone by binding to the melanocortin-1 receptor on melanocytes and activating the synthesis of eumelanin. Eumelanin provides photoprotection through mechanisms including, but not limited to, the absorption and scattering of visible and UV light and antioxidant activity. Afamelanotide increases eumelanin density in healthy volunteers and patients with erythropoietic protoporphyria. In healthy, fair-skinned volunteers, a significant increase in melanin density and skin darkening in both sun-exposed and non-sun-exposed sites was seen with subcutaneous injections of afamelanotide. The most common afamelanotide adverse events included headache and nausea. Common adverse effects include back pain, upper respiratory tract infections, decreased appetite, migraine, and dizziness.   NCATS

Chemistry

  • SMILES: CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(N)=O
  • InChIKey: UAHFGYDRQSXQEB-LEBBXHLNSA-N
  • Mol. Mass: 1646.8452
  • ALogP: Missing data
  • ChEMBL Molecule:
    afamelanotide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

afamelanotide | cuv1647 | melanotan 1 | melanotan i | mt-i | scenesse

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Protoporphyria, Erythropoietic (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Acne Vulgaris (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Healthy Volunteers (Phase 1)

Ischemic Stroke (Phase 2)

Keratosis, Actinic (Phase 2)

Organ Transplantation (Phase 2)

Polymorphism, Genetic (Phase 3)

Porphyria, Variegate (Phase 2)

Protoporphyria, Erythropoietic (Phase 3)

Sodium (Phase 2)

Sunlight (Phase 3)

Urticaria (Phase 2)

Vitiligo (Phase 3)

Xeroderma Pigmentosum (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue